Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02973399
Title Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Esanex Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.